September 30, 2008 - Collaboration Will Guide Innovation for Development of Assays to Treat Complex Disease; Cellular Systems Biology Approach to Enable More Physiologically Relevant Drug Screening - Cellumen, Inc. announced an agreement with the Alzheimer’s Drug Discovery Foundation (ADDF) to apply Cellumen’s Cellular Systems Biology (CSB) technology to create a cellular model of Alzheimer’s disease. The main objective of the partnership is for Cellumen to develop a panel of CSB assays, as well as biosensors of key protein:protein interactions, that reveal the activity of multiple targets and pathways implicated in Alzheimer’s disease in an intact, functioning cellular system... [PDF] Cellumen's Press Release -
